{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:22:53Z","timestamp":1794057773828,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,8,3]],"date-time":"2007-08-03T00:00:00Z","timestamp":1186099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2007,11,19]]},"DOI":"10.1007\/s00417-007-0660-z","type":"journal-article","created":{"date-parts":[[2007,8,2]],"date-time":"2007-08-02T12:19:44Z","timestamp":1186057184000},"page":"81-87","source":"Crossref","is-referenced-by-count":355,"title":["Twelve-month safety of intravitreal injections of bevacizumab (Avastin\u00ae): results of the Pan-American Collaborative Retina Study Group (PACORES)"],"prefix":"10.1007","volume":"246","author":[{"given":"Lihteh","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A.","family":"Mart\u00ednez-Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Quiroz-Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Fernando","family":"Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda H.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel E.","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Pan American Collaborative Retina Group (PACORES)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,3]]},"reference":[{"key":"660_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1023\/A:1009071601454","volume":"3","author":"AP Adamis","year":"1999","unstructured":"Adamis AP, Aiello LP, D\u2019Amato RA (1999) Angiogenesis and ophthalmic disease. Angiogenesis 3:9\u201314","journal-title":"Angiogenesis"},{"key":"660_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111\u2013118","journal-title":"Retina"},{"key":"660_CR3","first-page":"2408","volume":"42","author":"T Qaum","year":"2001","unstructured":"Qaum T, Xu Q, Joussen AM, et al (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408\u20132413","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"660_CR4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jcp.10246","volume":"195","author":"Y Saishin","year":"2003","unstructured":"Saishin Y, Saishin Y, Takahashi K, et al (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241\u2013248","journal-title":"J Cell Physiol"},{"key":"660_CR5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","volume":"112","author":"ET Cunningham Jr","year":"2005","unstructured":"Cunningham ET Jr, Adamis AP, Altaweel M, et al (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747\u20131757","journal-title":"Ophthalmology"},{"key":"660_CR6","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816","journal-title":"N Engl J Med"},{"issue":"642","key":"660_CR7","first-page":"e1","volume":"113","author":"JS Heier","year":"2006","unstructured":"Heier JS, Antoszyk AN, Pavan PR, et al (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study. Ophthalmology 113(642):e1\u2013e4","journal-title":"Ophthalmology"},{"key":"660_CR8","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"660_CR9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035\u20131047","journal-title":"Ophthalmology"},{"key":"660_CR10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336\u2013339","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"660_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331\u2013335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"660_CR12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00006982-200410001-00002","volume":"24","author":"LP Aiello","year":"2004","unstructured":"Aiello LP, Brucker AJ, Chang S, et al (2004) Evolving guidelines for intravitreous injections. Retina 24:S3\u201319","journal-title":"Retina"},{"key":"660_CR13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1007657109012","volume":"17","author":"DW Drolet","year":"2000","unstructured":"Drolet DW, Nelson J, Tucker CE, et al (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17:1503\u20131510","journal-title":"Pharm Res"},{"key":"660_CR14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"J Gaudreault","year":"2005","unstructured":"Gaudreault J, Fei D, Rusit J, et al (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726\u2013733","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"660_CR15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","volume":"293","author":"P Wijngaarden van","year":"2005","unstructured":"van Wijngaarden P, Coster DJ, Williams KA (2005) Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293:1509\u20131513","journal-title":"JAMA"},{"key":"660_CR16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-004-2699-3","volume":"7","author":"DC Sane","year":"2004","unstructured":"Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7:193\u2013201","journal-title":"Angiogenesis"},{"key":"660_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0420.2006.00819.x","volume":"85","author":"M Kernt","year":"2007","unstructured":"Kernt M, Neubauer AS, Kampik A (2007) Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85:119\u2013120","journal-title":"Acta Ophthalmol Scand"},{"key":"660_CR18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nbt1004-1198","volume":"22","author":"M Ratner","year":"2004","unstructured":"Ratner M (2004) Genentech discloses safety concerns over Avastin. Nat Biotechnol 22:1198","journal-title":"Nat Biotechnol"},{"key":"660_CR19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90:1344\u20131349","journal-title":"Br J Ophthalmol"},{"key":"660_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Laud K, Fine HF, et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383\u2013390","journal-title":"Retina"},{"issue":"3","key":"660_CR21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3):363\u2013372 e5","journal-title":"Ophthalmology"},{"key":"660_CR22","unstructured":"(2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198\u2013207"},{"key":"660_CR23","doi-asserted-by":"crossref","unstructured":"(2001)Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541\u2013560","DOI":"10.1016\/S0002-9394(01)00967-9"},{"key":"660_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ophtha.2005.10.019","volume":"11","author":"JS Slakter","year":"2006","unstructured":"Slakter JS, Bochow TW, D\u2019Amico DJ, et al (2006)Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 11:3\u201313","journal-title":"Ophthalmology"},{"key":"660_CR25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ohc.2006.05.009","volume":"19","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19:361\u2013372","journal-title":"Ophthalmol Clin North Am"},{"key":"660_CR26","unstructured":"Geiss LS, Herman WH, PJS (2007) Mortality in Non-Insulin Dependent Diabetes. Diabetes in America, 2nd Ed. http:\/\/diabetes.niddk.nih.gov\/dm\/pubs\/america\/pdf\/chapter11.pdf. Accessed February 14"},{"key":"660_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"RP Manzano","year":"2006","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257\u2013261","journal-title":"Retina"},{"key":"660_CR28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G, et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"},{"key":"660_CR29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00006982-200603000-00003","volume":"26","author":"RK Maturi","year":"2006","unstructured":"Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270\u2013274","journal-title":"Retina"},{"key":"660_CR30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.iae.0000222547.35820.52","volume":"26","author":"S Luthra","year":"2006","unstructured":"Luthra S, Narayanan R, Marques LE, et al (2006) Evaluation of in vitro effects of bevacizumab (avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26:512\u2013518","journal-title":"Retina"},{"key":"660_CR31","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/bjo.2006.094995","volume":"90","author":"M Luke","year":"2006","unstructured":"Luke M, Warga M, Ziemssen F, et al (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90:1178\u20131182","journal-title":"Br J Ophthalmol"},{"key":"660_CR32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","volume":"24","author":"RD Jager","year":"2004","unstructured":"Jager RD, Aiello LP, Patel SC, Cunningham ET Jr (2004) Risks of intravitreous injection: a comprehensive review. Retina 24:676\u2013698","journal-title":"Retina"},{"key":"660_CR33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bjo.2006.092262","volume":"90","author":"F Ziemssen","year":"2006","unstructured":"Ziemssen F, Warga M, Neuhann IM, et al (2006) Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function? Br J Ophthalmol 90:922","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0660-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-007-0660-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0660-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:38:38Z","timestamp":1737340718000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-007-0660-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,11,19]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s00417-007-0660-z","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,3]]}}}